

Thomas C Hanff

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8663095/publications.pdf>

Version: 2024-02-01

27
papers

1,027
citations

687363

13
h-index

552781

26
g-index

27
all docs

27
docs citations

27
times ranked

2131
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel Risk Model to Predict Emergency Department Associated Mortality for Patients Supported With a Ventricular Assist Device: The Emergency Departmentâ€“Ventricular Assist Device Risk Score. Journal of the American Heart Association, 2022, 11, e020942.	3.7	1
2	Coronavirus disease 2019 is delaying the diagnosis and management of chest pain, acute coronary syndromes, myocarditis and heart failure. Future Cardiology, 2021, 17, 3-6.	1.2	7
3	Quantitative Proteomic Analysis of Diabetes Mellitus in Heart Failure With Preserved Ejection Fraction. JACC Basic To Translational Science, 2021, 6, 89-99.	4.1	18
4	An Increasing Burden of Disease: Emergency Department Visits Among Patients With Ventricular Assist Devices From 2010 to 2017. Journal of the American Heart Association, 2021, 10, e018035.	3.7	7
5	Venoarterial Extracorporeal Membrane Oxygenation to Heart Transplantâ€“An Inflamed Bridge?â€“Reply. JAMA Cardiology, 2021, 6, 362.	6.1	0
6	Continuation versus discontinuation of reninâ€“angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. Lancet Respiratory Medicine, the, 2021, 9, 275-284.	10.7	198
7	Characteristics and Outcomes of COVID-19 in Patients on Left Ventricular Assist Device Support. Circulation: Heart Failure, 2021, 14, e007957.	3.9	24
8	Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans. PLoS ONE, 2021, 16, e0248080.	2.5	17
9	Multimodality assessment of heart failure with preserved ejection fraction skeletal muscle reveals differences in the machinery of energy fuel metabolism. ESC Heart Failure, 2021, 8, 2698-2712.	3.1	16
10	Association of Health Insurance Payer Type and Outcomes After Durable Left Ventricular Assist Device Implantation: An Analysis of the STS-INTERMACS Registry. Circulation: Heart Failure, 2021, 14, e008277.	3.9	1
11	Coronavirus disease 2019 in heart transplant recipients: Risk factors, immunosuppression, and outcomes. Journal of Heart and Lung Transplantation, 2021, 40, 926-935.	0.6	36
12	Mental health disorders and emergency resource use and outcomes in ventricular assist device supported patients. American Heart Journal, 2021, 240, 11-15.	2.7	1
13	Clinical and Proteomic Correlates of Plasma ACE2 (Angiotensin-Converting Enzyme 2) in Human Heart Failure. Hypertension, 2020, 76, 1526-1536.	2.7	39
14	Update to an early investigation of outcomes with the new 2018 donor heart allocation system in the United States. Journal of Heart and Lung Transplantation, 2020, 39, 725-726.	0.6	42
15	Thrombosis in <scp>COVID</scp>â€“19. American Journal of Hematology, 2020, 95, 1578-1589.	4.1	235
16	Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	2.5	15
17	The effect of transfusion of blood products on ventricular assist device support outcomes. ESC Heart Failure, 2020, 7, 3573-3581.	3.1	11
18	Trends in Mechanical Support Use as a Bridge to Adult Heart Transplant Under New Allocation Rules. JAMA Cardiology, 2020, 5, 728.	6.1	48

#	ARTICLE	IF	CITATIONS
19	Response by Cohen et al to Letter Regarding Article, "Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19". <i>Circulation Research</i> , 2020, 126, e140-e141.	4.5	11
20	Is There an Association Between COVID-19 Mortality and the Renin-Angiotensin System? A Call for Epidemiologic Investigations. <i>Clinical Infectious Diseases</i> , 2020, 71, 870-874.	5.8	202
21	Relationship Between ACE2 and Other Components of the Renin-Angiotensin System. <i>Current Hypertension Reports</i> , 2020, 22, 44.	3.5	14
22	Reply to Tedeschi et al. <i>Clinical Infectious Diseases</i> , 2020, 71, 901-901.	5.8	2
23	Left Ventricular Assist Device as Destination Therapy: a State of the Science and Art of Long-Term Mechanical Circulatory Support. <i>Current Heart Failure Reports</i> , 2019, 16, 168-179.	3.3	20
24	Assessment of Predictors of Left Atrial Volume Response to a Transcatheter InterAtrial Shunt Device (from the REDUCE LAP-HF Trial). <i>American Journal of Cardiology</i> , 2019, 124, 1912-1917.	1.6	13
25	Predicting Long Term Outcome in Patients Treated With Continuous Flow Left Ventricular Assist Device: The Penn State Columbia Risk Score. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	30
26	Prognostic Implications of Changes in Albumin Following Left Ventricular Assist Device Implantation in Patients With Severe Heart Failure. <i>American Journal of Cardiology</i> , 2017, 120, 2003-2007.	1.6	9
27	Comparison of Causes of Death After Heart Transplantation in Patients With Left Ventricular Ejection Fractions $\leq 35\%$ Versus $> 35\%$. <i>American Journal of Cardiology</i> , 2016, 117, 1322-1326.	1.6	10